Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Integrative genome comparison of primary and metastatic melanomas.

Kabbarah O, Nogueira C, Feng B, Nazarian RM, Bosenberg M, Wu M, Scott KL, Kwong LN, Xiao Y, Cordon-Cardo C, Granter SR, Ramaswamy S, Golub T, Duncan LM, Wagner SN, Brennan C, Chin L.

PLoS One. 2010 May 24;5(5):e10770. doi: 10.1371/journal.pone.0010770.

2.

Differential gene expression profiling of primary cutaneous melanoma and sentinel lymph node metastases.

Koh SS, Wei JP, Li X, Huang RR, Doan NB, Scolyer RA, Cochran AJ, Binder SW.

Mod Pathol. 2012 Jun;25(6):828-37. doi: 10.1038/modpathol.2012.32.

3.

A gene expression signature of invasive potential in metastatic melanoma cells.

Jeffs AR, Glover AC, Slobbe LJ, Wang L, He S, Hazlett JA, Awasthi A, Woolley AG, Marshall ES, Joseph WR, Print CG, Baguley BC, Eccles MR.

PLoS One. 2009 Dec 24;4(12):e8461. doi: 10.1371/journal.pone.0008461.

4.

Multiple metastases from cutaneous malignant melanoma patients may display heterogeneous genomic and epigenomic patterns.

Harbst K, Staaf J, Måsbäck A, Olsson H, Ingvar C, Vallon-Christersson J, Ringnér M, Borg A, Jönsson G.

Melanoma Res. 2010 Oct;20(5):381-91.

PMID:
20848731
5.

Gene signature of the metastatic potential of cutaneous melanoma: too much for too little?

Tímár J, Gyorffy B, Rásó E.

Clin Exp Metastasis. 2010 Aug;27(6):371-87. doi: 10.1007/s10585-010-9307-2. Review.

PMID:
20177751
6.

Use of integrative epigenetic and cytogenetic analyses to identify novel tumor-suppressor genes in malignant melanoma.

Mithani SK, Smith IM, Califano JA.

Melanoma Res. 2011 Aug;21(4):298-307. doi: 10.1097/CMR.0b013e328344a003.

7.

Chromosomal imbalances in primary and metastatic melanomas revealed by comparative genomic hybridization.

Balázs M, Adám Z, Treszl A, Bégány A, Hunyadi J, Adány R.

Cytometry. 2001 Aug 15;46(4):222-32.

PMID:
11514955
8.

A metastasis modifier locus on human chromosome 8p in uveal melanoma identified by integrative genomic analysis.

Onken MD, Worley LA, Harbour JW.

Clin Cancer Res. 2008 Jun 15;14(12):3737-45. doi: 10.1158/1078-0432.CCR-07-5144.

9.

The impact of genomics in understanding human melanoma progression and metastasis.

Ren S, Liu S, Howell P Jr, Xi Y, Enkemann SA, Ju J, Riker AI.

Cancer Control. 2008 Jul;15(3):202-15. Review.

10.
11.

Proinvasion metastasis drivers in early-stage melanoma are oncogenes.

Scott KL, Nogueira C, Heffernan TP, van Doorn R, Dhakal S, Hanna JA, Min C, Jaskelioff M, Xiao Y, Wu CJ, Cameron LA, Perry SR, Zeid R, Feinberg T, Kim M, Vande Woude G, Granter SR, Bosenberg M, Chu GC, DePinho RA, Rimm DL, Chin L.

Cancer Cell. 2011 Jul 12;20(1):92-103. doi: 10.1016/j.ccr.2011.05.025.

12.

Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival.

Dadras SS, Paul T, Bertoncini J, Brown LF, Muzikansky A, Jackson DG, Ellwanger U, Garbe C, Mihm MC, Detmar M.

Am J Pathol. 2003 Jun;162(6):1951-60.

13.

Decreased expression of Apaf-1 with progression of melanoma.

Mustika R, Budiyanto A, Nishigori C, Ichihashi M, Ueda M.

Pigment Cell Res. 2005 Feb;18(1):59-62.

PMID:
15649154
14.

Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.

Lázár V, Ecsedi S, Vízkeleti L, Rákosy Z, Boross G, Szappanos B, Bégány A, Emri G, Adány R, Balázs M.

Melanoma Res. 2012 Jun;22(3):202-14. doi: 10.1097/CMR.0b013e328352dbc8.

PMID:
22456166
15.

Gene expression profiling of primary cutaneous melanoma and clinical outcome.

Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, Eggermont AM, Lenoir G, Sarasin A, Tursz T, van den Oord JJ, Spatz A; Melanoma Group of the European Organization for Research and Treatment of Cancer..

J Natl Cancer Inst. 2006 Apr 5;98(7):472-82.

16.

Deregulation of glyceraldehyde-3-phosphate dehydrogenase expression during tumor progression of human cutaneous melanoma.

Ramos D, Pellín-Carcelén A, Agustí J, Murgui A, Jordá E, Pellín A, Monteagudo C.

Anticancer Res. 2015 Jan;35(1):439-44.

PMID:
25550585
17.

Aggressiveness of human melanoma xenograft models is promoted by aneuploidy-driven gene expression deregulation.

Mathieu V, Pirker C, Schmidt WM, Spiegl-Kreinecker S, Lötsch D, Heffeter P, Hegedus B, Grusch M, Kiss R, Berger W.

Oncotarget. 2012 Apr;3(4):399-413.

18.

The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis.

Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, Morris C, Xi Y, Howell P, Metge B, Samant RS, Shevde LA, Li W, Eschrich S, Daud A, Ju J, Matta J.

BMC Med Genomics. 2008 Apr 28;1:13. doi: 10.1186/1755-8794-1-13.

19.

Genotypic analysis of primary and metastatic cutaneous melanoma.

Rao UN, Jones MW, Finkelstein SD.

Cancer Genet Cytogenet. 2003 Jan 1;140(1):37-44.

PMID:
12550756
20.

Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues.

Jaeger J, Koczan D, Thiesen HJ, Ibrahim SM, Gross G, Spang R, Kunz M.

Clin Cancer Res. 2007 Feb 1;13(3):806-15.

Items per page

Supplemental Content

Support Center